News | Ventricular Assist Devices (VAD) | October 06, 2015

Aortix Heart Failure Pump Chosen for TCT “Shark Tank” Competition

Panel of judges will vote on the best technological concepts of the year
 

Aortix device, TCT, Interventional Innovation Shark Tank Competition, catheter-based circulatory heart pump

Image courtesy of Procyrion

October 6, 2015 — The novel Aortix device has earned a spot among the diagnostic and therapeutic modalities accepted for presentation in the Interventional Innovation “Shark Tank” Competition at the Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium. The event will be held Tuesday, Oct. 13, in San Francisco, California.

Developed by Procyrion Inc., Aortix is designed to be the first catheter-based circulatory heart pump specifically for New York Heart Association (NYHA) Class III-IVa heart failure patients who are too sick for medication alone, but not sick enough for risky surgical interventions. The small but powerful micro-pump is deployed downstream of the carotid arteries, which has the potential to eliminate major risks associated with thrombotic strokes, and the device is suitable for ambulatory use.

Duke University cardiologist and Procyrion Scientific Advisory Board member Manesh Patel, M.D., will have eight minutes to present the novel booster pump before a unique group of reviewers who will select the best technological concepts of the year. The top three finalists will be selected to answer additional questions from the judges and the winner and first-runner up will be announced Thursday, Oct. 15.

The Aortix device is not approved for use or sale.

For more information: www.procyrion.com

Related Content

MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Sponsored Content | Videos | Cardiovascular Ultrasound| August 28, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Aug.
Overlay Init